A review of the literature indicates that published data on the pharmacoeconomics of PMO therapy in the U.S. are limited and inconclusive. Most pharmacoeconomic analyses were conducted retrospectively or were cost-model studies, and most analyses focused on alendronate canadian. Pharmacoeconomic studies are summarized in Table 4. Only one prospective pharmacoeconomic evaluation was identified in the […]
Calcitonin Cacitonin-Salmon (Miacalcin, Fortical) Calcitonin-salmon (Miacalcin, Novartis; Fortical, Upsher Smith) is a synthetic polypeptide of 32 amino acids found in salmon calcitonin. It is available in the U.S. in an intranasal form for daily use and in subcutaneous form for every-other-day use. Calcitonin decreases bone resorption by reducing the activity and the number of […]
Alendronate and Alendronate/Cholecalciferol (Fosamax Plus D) The safety and fracture efficacy of alendronate in the treatment of PMO were established with the Alendronate Phase 3 Group trials and the Fracture Intervention Trial (FIT). Data from the three-year trials were combined to determine a reduced fracture risk. A total of 994 postmenopausal women were randomly assigned […]
Pharmacological treatment recommendations to prevent fractures in women with PMO include: antiresorptive agents: bisphosphonates, selective estrogen receptor modulators (SERMs), and calcitonin. bone anabolic agents: the parathyroid hormone (PTH) therapeutic class. Until evidence of risks of cardiovascular disease and breast cancer associated with hormone replacement therapy (HRT) was published in 2003, HRT had been recommended for […]
Efficacy Drugs that have proved effective in preventing fractures in women with PMO. Antiresorptive drugs reduced rates of vertebral fractures by 30% to 70%, and teriparatide reduced these rates by 65% to 69%. Efficacy of treatment in preventing fractures was seen relatively early, typically within 12 to 18 months. However, several extension trials suggest that […]
We performed a librarian-conducted Medline search to identify literature on the efficacy and economics of PMO treatment from 1995 to 2006. Other databases included International Pharmaceutical Abstracts; Business Source Premier; and Research Digest, from the International Society for Pharma-coeconomics and Outcomes Research.
It is defined as a disease of the skeletal system, characterized by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue that can lead to enhanced bone fragility and a consequent increase in fracture risk. In the U.S., 54% of postmenopausal white women are os-teopenic and 30% are osteoporotic. A 50-year-old white woman […]